Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans

Viral Immunology

Volumn 29, Issue 4, 2016, Pages 259-262

  Zhong, Weimin ^a   Gross, F Liaini ^a   Holiday, Crystal ^a   Jefferson, Stacie N ^a   Bai, Yaohui ^a   Liu, Feng ^a   Katz, Jacqueline M ^a   Levine, Min Z ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; CROSS REACTING ANTIBODY; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; INACTIVATED VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENIC VARIATION; ARTICLE; FEMALE; HUMAN; INFLUENZA A VIRUS (H3N2); INFLUENZA VACCINATION; MALE; NONHUMAN; NORMAL HUMAN; PASSIVE TRANSPORT; VIRUS NEUTRALIZATION; BLOOD; CROSS PROTECTION; CROSS REACTION; GENETICS; IMMUNOLOGY; INFLUENZA; MIDDLE AGED; PROCEDURES; VACCINATION; VIROLOGY; YOUNG ADULT;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, VIRAL; CROSS PROTECTION; CROSS REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINATION; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84969150885     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2016.0003     Document Type: Article

References (23)

1. Binyamin L, Alpaugh RK, Hughes TL, et al. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol 2008;180:6392-6401.
2. Castilla J, Godoy P, Dominguez A, et al. Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratory-confirmed influenza. Clin Infect Dis 2013;57:167-175.
3. Chambers BS, Parkhouse K, Ross TM, et al. Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014-2015 influenza season. Cell 2015; 12:1-6.
4. Deiss RG, Arnold JC, Chen WJ, et al. Vaccine-associated reduction in symptom severity among patients with influenza A/H3N2 disease. Vaccine 2015;33:7160-7167.
5. D'Mello T, Brammer L, Blanton L, et al. Update: influenza activity-United States, September 28, 2014-February 21, 2015. MMWR Morb Mortal Wkly Rep 2015;64:206-212.
6. Dormitzer PR, Galli G, Castellino F, et al. Influenza vaccine immunology. Immunol Rev 2011;239:167-177.
7. Ducatez MF, Webb A, Crumpton JC, Webby RJ. Longterm vaccine-induced heterologous protection against H5N1 influenza viruses in the ferret model. Influenza Other Respir Viruses 2013;7:506-512.
8. Ellebedy AH, Ducatez MF, Duan S, et al. Impact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets. Vaccine 2011;29:3335-3339.
9. Endo A, Itamura S, Iinuma H, et al. Homotypic and heterotypic protection against influenza virus infection in mice by recombinant vaccinia virus expressing the haemagglutinin or nucleoprotein of influenza virus. J Gen Virol 1991;72 (Pt 3):699-703.
10. Ferdinands JM, Olsho LE, Agan AA, et al. Effectiveness of influenza vaccine against life-threatening RT-PCR-confirmed influenza illness in US children, 2010-2012. J Infect Dis 2014;210:674-683.
11. Flannery B, Clippard J, Zimmerman RK, et al. Early estimates of seasonal influenza vaccine effectiveness-United States, January 2015. MMWR Morb Mortal Wkly Rep 2015;64:10-15.
12. Hensley SE. Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories. Curr Opin Virol 2014;8:85-89.
13. Jegaskanda S, Laurie KL, Amarasena TH, et al. Ageassociated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. J Infect Dis 2013;208:1051-1061.
14. Jegaskanda S, Vandenberg K, Laurie KL, et al. Crossreactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses. J Infect Dis 2014;210:1811-1822.
15. Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ. Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J Virol 2013;87:5512-5522.
16. Kostova D, Reed C, Finelli L, et al. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005-2011. PLoS One 2013;8:e66312.
17. Krammer F, Jul-Larsen A, Margine I, et al. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clin Vaccine Immunol 2014;21:1153-1163.
18. Larson HE, Tyrrell DA, Bowker CH, et al. Immunity to challenge in volunteers vaccinated with an inactivated current or earlier strain of influenza A(H3N2). J Hyg (London) 1978.80:243-248.
19. Lin YP, Gregory V, Collins P, et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J Virol 2010; 84:6769-6781.
20. Lipatov AS, Hoffmann E, Salomon R, et al. Crossprotectiveness and immunogenicity of influenza A/Duck/ Singapore/3/97(H5) vaccines against infection with A/Vietnam/ 1203/04(H5N1) virus in ferrets. J Infect Dis 2006;194: 1040-1043.
21. O'Donnell CD, Wright A, Vogel LN, et al. Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus. J Virol 2012;86:8625-8633.
22. WHO Global Influenza Surveillance Network. Serological diagnosis of influenza by microneutralization assay. In: Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza. Geneva, Switzerland: WHO 2011:63-77.
23. Yassine HM, Boyington JC, McTamney PM, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 2015;21:1065-1070.